**Revenue distribution by sectors:**
- **Pharmaceutical products:** approx. 70%
- **Biotechnology:** approx. 20%
- **Healthcare services:** approx. 10%

**TOP 3 markets and their percentage shares:**
- **South Korea:** approx. 50%
- **USA:** approx. 25%
- **China:** approx. 15%

Daewoong Co., Ltd. generates the majority of its revenues from the pharmaceutical industry, with a significant portion also coming from biotechnology and healthcare services. The domestic market of South Korea remains the largest single market, followed by the USA and China, which also make significant contributions to the total revenue. This distribution demonstrates a strong international presence and strategic focus on high-growth markets.

**Production sites of Daewoong Co., Ltd.:**

Daewoong Co., Ltd. mainly produces its products in South Korea. The company operates several production facilities, including significant plants in Hwaseong and Hyangnam. These sites specialize in the manufacturing of pharmaceutical products and biopharmaceutical products.

In addition, in recent years, Daewoong Co., Ltd. has expanded its production capacities through international partnerships and joint ventures to better serve the global market. This includes collaborations in Southeast Asia and other strategic markets.

**Focus on Research and Development:** 20% of revenue (estimated 2026)
**International Expansion:** Target markets Asia and North America
**Partnerships and Collaborations:** Strengthened in recent years

Daewoong Co., Ltd. pursues a strategy that is heavily focused on research and development (R&D) to develop innovative pharmaceutical products. The company invests an estimated 20% of its revenue in R&D to expand its product pipeline and bring new therapies to the market.

In addition, Daewoong aims for increased international expansion, particularly in the Asian and North American markets. These regions offer great potential for growth and market penetration, supported by targeted marketing strategies and local partnerships.

Another strategic focus is on forming partnerships and collaborations with other pharmaceutical companies and research institutions. This collaboration enables Daewoong to leverage synergies and accelerate the development of new products.

**Main raw materials:** Pharmaceutical active ingredients, chemicals

**Countries of origin:** China, India, Germany

Daewoong Co., Ltd. is a significant company in the pharmaceutical industry specializing in the manufacturing of drugs. The main raw materials imported include pharmaceutical active ingredients and special chemicals necessary for the production of medications.

China and India are leading suppliers of pharmaceutical active ingredients due to their well-developed chemical industry and cost-effective production capacities. Germany is often mentioned as a source of high-quality chemicals and specialized pharmaceutical products used in drug manufacturing.

Daewoong Co., Ltd. ensures the quality and competitiveness of its products in the global market by importing these materials from various countries.

**Market Share in the Pharmaceutical Industry (South Korea):** Approximately 5-7% (estimated, 2026)

**R&D Investments:** 12% of revenue (2025)

Daewoong Co., Ltd. is one of the leading pharmaceutical companies in South Korea and has gained a significant competitive advantage through its strong research and development investments. With an estimated market share of 5-7% in the South Korean pharmaceutical industry, the company positions itself as a significant player.

A key aspect of Daewoong's competitive advantage is the continuous investment in research and development, accounting for about 12% of revenue. These investments enable the company to develop and launch innovative drugs, strengthening its market position.

Additionally, Daewoong benefits from strategic partnerships and a diversified product portfolio, allowing the company to adapt flexibly to market changes and seize new growth opportunities.

**Institutional Investor Share:** Estimated around 35-40% (2026)

**Insider Buys/Sells:** No specific data available (2026)

The institutional investor share in Daewoong Co., Ltd. is estimated to be between 35% and 40%. This is typical for companies in the industry, as institutional investors often invest in established companies to benefit from stable returns.

There is no specific data available on insider buys or sells in 2026. However, such transactions typically can provide significant insights into the management's confidence in the company's future development. It is advisable to regularly check the releases of the Korean stock exchange or company reports to obtain current information.

**Market share of Daewoong Co., Ltd.:** Estimated 5-7% (2026)

**Top competitors and their market shares:**
1. **Samsung Biologics**: 20-25%
2. **Celltrion**: 15-20%
3. **Hanmi Pharmaceutical**: 10-12%
4. **LG Chem (Life Sciences Division)**: 8-10%
5. **SK Biopharmaceuticals**: 6-8%
6. **Daewoong Co., Ltd.**: 5-7%
7. **GC Pharma**: 4-6%
8. **Yuhan Corporation**: 3-5%
9. **Korea United Pharm**: 2-4%
10. **Dong-A ST**: 2-3%

**Moat of Daewoong Co., Ltd.:**

Daewoong Co., Ltd. has a moderate moat, mainly based on its strong R&D department and a wide range of products. In recent years, the company has invested in innovative technologies and international partnerships to strengthen its market position.

However, compared to its competitors, Daewoong has a less pronounced moat. Companies like Samsung Biologics and Celltrion have larger production capacities and a stronger international presence, giving them a significant advantage. Additionally, these companies benefit from more extensive resources and networks that help them respond faster to market changes.

Daewoong must continue to invest in research and development and expand its global reach to strengthen its moat and compete against larger competitors.

**Revenue Growth:** 8.5% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in South Korea:** 15% (2025)

Daewoong Co., Ltd. recorded a revenue growth of 8.5% in 2025, attributed to strong demand for their pharmaceutical products and successful market expansion. The company continues to heavily invest in research and development, accounting for 12% of revenue. These investments could foster future growth opportunities through new products and innovations.

Daewoong's market share in South Korea stands at 15%, indicating a solid market position. This position could be further strengthened through strategic partnerships and international expansion. Analysts view the strong R&D ratio and market position as positive indicators of long-term growth potential.

In summary, Daewoong Co., Ltd. could be an attractive investment for investors focusing on long-term growth and innovation. The strong market position and continuous investments in research and development support this assessment.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Stable over the last 5 years

Daewoong Co., Ltd. has pursued a stable dividend policy in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on historical payouts and current market conditions.

The company has regularly paid dividends over the past five years, indicating a reliable payout. This stability is supported by a solid financial foundation and continuous business development. Analysts expect Daewoong to continue to be able to distribute dividends at a similar level in the future, provided no unexpected economic challenges arise.